Full text is available at the source.
Forsythiaside A alleviated carbon tetrachloride-induced liver fibrosis by modulating gut microbiota composition to increase short-chain fatty acids and restoring bile acids metabolism disorder
Forsythiaside A may reduce liver scarring caused by carbon tetrachloride by changing gut bacteria to boost short-chain fatty acids and fix bile acid metabolism
AI simplified
Abstract
Forsythiaside A (FTA) significantly attenuated carbon tetrachloride (CCl)-induced liver fibrosis in mice.
- Liver fibrosis was induced in mice using an intraperitoneal injection of 2 mL/kg CCl three times a week for 4 weeks.
- FTA reduced markers of liver fibrosis as indicated by Masson and Sirius red staining and assays for liver hydroxyproline and various collagen types.
- Treatment with FTA inhibited the activation of hepatic stellate cells and decreased hepatic inflammation and oxidative stress.
- FTA improved gut health by reducing CCl-induced dysbiosis, enhancing intestinal barrier function, and increasing short-chain fatty acid production.
- Serum lipopolysaccharide levels decreased, and expression of ileal tight junction proteins increased following FTA treatment.
- FTA may modulate genes related to bile acid metabolism and alter the distribution of fecal bile acids in fibrotic mice.
AI simplified